Globenewswire·2025-09-17 05:00Core Insights - Sanofi's brivekimig demonstrated positive results in the phase 2a HS-OBTAIN study for treating moderate-to-severe hidradenitis suppurativa (HS) [2][4][10] - The treatment showed clinically meaningful improvements in the primary endpoint, HiSCR50, with a median response rate of 67% in the brivekimig group compared to 37% in the placebo group [8] - Brivekimig was well tolerated, with no serious adverse events reported, and the most common adverse events were nasopharyngitis and headache [5][6] Study Details - The HS-OBTAIN study was a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of brivekimig in biologic-naïve adults with moderate-to-severe HS [10][11] - Patients were randomized 2:1 to receive brivekimig 150 mg or placebo subcutaneously every two weeks for 16 weeks [11] - Key secondary endpoints also showed significant improvements, with 54% of patients achieving HiSCR75 and 31% achieving HiSCR90 in the brivekimig group compared to 22% and 9% in the placebo group, respectively [8] Mechanism and Future Directions - Brivekimig is a dual-target Nanobody® molecule that inhibits tumor necrosis factor (TNF) and OX40-ligand, which are crucial in inflammatory pathways [7][9] - The results indicate that targeting both TNF and OX40L pathways may provide a promising strategy for reducing inflammation in HS [4][6] - Sanofi is committed to exploring brivekimig further and its potential impact on chronic inflammatory skin diseases [6][12]